Please login to the form below

Not currently logged in
Email:
Password:

Coversyl

This page shows the latest Coversyl news and features for those working in and with pharma, biotech and healthcare.

Lundbeck challenge to EC pay-for-delay ruling fails

Lundbeck challenge to EC pay-for-delay ruling fails

Servier's Coversyl/Aceon (perindopril) that involved four generic drugmakers.

Latest news

  • EU hits Servier and generic firms with €428m 'pay-for-delay' fine EU hits Servier and generic firms with €428m 'pay-for-delay' fine

    EU hits Servier and generic firms with 428m 'pay-for-delay' fine. Follows deals to delay competition for blood pressure drug Coversyl/Aceon. ... in preventing more affordable copies of blood pressure drug Coversyl/Aceon (perindopril) from reaching the

  • EC fines J&J and Novartis in pay-for-delay case EC fines J&J and Novartis in pay-for-delay case

    Almunia noted that the EC continues to pursue cases against Servier and several generic companies concerning the cardiovascular medicine Coversyl/Aceon (perindopril), as well as Cephalon and Teva concerning narcolepsy treatment

  • EC to investigate Novartis and J&J in antitrust probe EC to investigate Novartis and J&J in antitrust probe

    Antitrust charges have also been laid against Servier and four generic companies in a case involving the French drugmaker's Coversyl/Aceon (perindopril) cardiovascular product and against Lundbeck and eight generics

  • EC lays formal antitrust charges against Servier

    EC lays formal antitrust charges against Servier. French firm accused of blocking entry of generic Coversyl/Aceon. ... French pharma company Servier has been formally charged by the European Commission of blocking the entry of generic versions of its

  • European Commission drops Servier misinformation investigation

    The case involved claims Servier breached EC rules on restrictive agreements and abused its dominant market position, delaying market entry for generic versions of the company's hypertension treatment Coversyl Arginine

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics